

# Chiara Romani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1396989/publications.pdf>

Version: 2024-02-01

57  
papers

2,258  
citations

249298

26  
h-index

252626

46  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3703  
citing authors

#	ARTICLE	IF	CITATIONS
1	VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2022, 12, 818613.	1.3	1
2	Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders. <i>Frontiers in Oncology</i> , 2022, 12, 886404.	1.3	1
3	<sc>L1CAM</sc> expression as a predictor of platinum response in high-risk endometrial carcinoma. <i>International Journal of Cancer</i> , 2022, 151, 637-648.	2.3	7
4	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
5	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. <i>Cancers</i> , 2021, 13, 906.	1.7	6
6	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
7	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021, 115, 105213.	0.8	33
8	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021, 21, 561.	1.1	5
9	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021, 13, 2527.	1.7	17
10	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3358.	1.7	9
11	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021, 11, 2987-2999.	4.6	37
12	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020, 9, 1828.	1.8	13
13	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1287.	1.3	9
14	Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 584022.	1.3	6
15	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 565-574.	2.3	15
16	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	3.3	52
17	FXD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 584-592.	2.9	30
18	EP1116...Integrated pathway analysis identifies a 3-gene signature predicting platinum response and outcome of high grade serous ovarian carcinoma patients. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	3.3	49
20	Claudin3 is localized outside the tight junctions in human carcinomas. <i>Oncotarget</i> , 2018, 9, 18446-18453.	0.8	15
21	Identification of optimal reference RNAs to normalize miRNA expression data by qRT-PCR in formalin-fixed, paraffin-embedded lymph node tissue. <i>Translational Cancer Research</i> , 2018, 7, S733-S734.	0.4	0
22	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 63.	3.5	53
23	Polymerase $\beta$ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	0.6	55
24	PO-102: EGFR detection in saliva as an easy diagnostic and prognostic tool in oral squamous cell cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 49.	0.3	0
25	Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer. <i>Laryngoscope</i> , 2017, 127, E408-E414.	1.1	29
26	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. <i>BMC Cancer</i> , 2017, 17, 366.	1.1	16
27	Identification of stably expressed reference small non-coding <i>scRNA</i> s for micro <i>scRNA</i> quantification in high-grade serous ovarian carcinoma tissues. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2341-2348.	1.6	50
28	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	3.3	181
29	The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. <i>Oncology Letters</i> , 2016, 12, 2493-2500.	0.8	14
30	Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. <i>Oncotarget</i> , 2015, 6, 34617-34628.	0.8	15
31	Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues. <i>PLoS ONE</i> , 2014, 9, e113781.	1.1	29
32	Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies. <i>Microbial Cell Factories</i> , 2014, 13, 140.	1.9	61
33	Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. <i>Journal of Translational Medicine</i> , 2013, 11, 162.	1.8	6
34	Class III $\beta$ -tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 62.e1-62.e9.	0.7	26
35	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2916-2921.	3.3	275
36	Prenatal presentation and postnatal evolution of a patient with Jansen metaphyseal dysplasia with a novel missense mutation in PTH1R. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2614-2619.	0.7	11

#	ARTICLE	IF	CITATIONS
37	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1815-24.	1.4	32
38	Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. <i>British Journal of Cancer</i> , 2013, 109, 462-471.	2.9	24
39	Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 2189-2198.	1.4	72
40	Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. <i>BMC Clinical Pathology</i> , 2012, 12, 22.	1.8	45
41	Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2496-2506.	1.1	112
42	8040 POSTER Diagnostic and Prognostic Significance of CA125 and HE4 in Ovarian Cancer Patients. <i>European Journal of Cancer</i> , 2011, 47, S539.	1.3	0
43	HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. <i>Clinica Chimica Acta</i> , 2011, 412, 1447-1453.	0.5	104
44	Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti-“Trop-2 Monoclonal Antibody. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1613-1621.	1.2	30
45	Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. <i>British Journal of Cancer</i> , 2011, 104, 1418-1425.	2.9	134
46	Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. <i>European Journal of Cancer</i> , 2010, 46, 944-953.	1.3	94
47	Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. <i>Journal of Virology</i> , 2009, 83, 6779-6789.	1.5	45
48	Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. <i>BMC Cancer</i> , 2009, 9, 253.	1.1	19
49	Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 70.e1-70.e9.	0.7	24
50	1315 Clinical role of human epididymis protein 4 (HE4) in epithelial ovarian cancer. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 143.	2.2	0
51	8016 Gene expression profile as a diagnostic tool for synchronous ovarian/endometrial cancer. <i>European Journal of Cancer</i> , Supplement, 2009, 7, 454.	2.2	0
52	Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1015-1021.	1.2	19
53	Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. <i>British Journal of Cancer</i> , 2008, 99, 768-773.	2.9	40
54	Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. <i>Gynecologic Oncology</i> , 2007, 106, 513-520.	0.6	77

#	ARTICLE	IF	CITATIONS
55	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives of Virology, 2006, 151, 1899-1916.	0.9	17
56	HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncology, 2006, 100, 469-478.	0.6	90
57	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology, 2006, 103, 405-416.	0.6	104